Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.

By R. Bergenstal, S. Garg, S. Weinzimer, B. Buckingham, B. Bode, W. Tamborlane, F. Kaufman. Journal of the American Medical Association (JAMA), 2016

600 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/413175a914e4bb6d229f198ab70f05094c2bebcb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Genetics

In Surgery

Citations in the corpus

International Consensus on Use of Continuous Glucose Monitoring (2017, background): “Increased glucose variability is consistently associated with mortality in the intensive care unit (73, 74) [C,B]”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. (2020, background): “temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults wit”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 (2019, background): “with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021, methodology): “HbA1c, TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage [89], with the greatest benefits seen with algorithmdriven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy [90, 91].”
Estimating Dynamic Treatment Regimes in Mobile Health Using V-learning (2016, methodology): “We envision application of this work for use before the artiﬁcial pancreas (Weinzimer et al., 2008; Kowalski, 2015; Bergenstal et al., 2016) becomes widely available.”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. (2021, background): “The safety and efficacy of hybrid closed-loop systems has been supported in the literature in adolescents and adults with type 1 diabetes (19,20), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia ov”